Navigation Links
MEI Pharma's Mitochondrial Inhibitor ME-344 Shows Preliminary Evidence of Single-Agent Activity in First-in-Human Clinical Study
Date:10/21/2013

SAN DIEGO, Oct. 21, 2013 /PRNewswire/ -- MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced results from a Phase I first-in-human, single-agent clinical study of its investigational mitochondrial inhibitor drug candidate, ME-344, in patients with refractory solid tumors. The results, presented yesterday at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, indicated that five of 21 evaluable patients treated with ME-344 experienced progression free survival (34 to 61+ weeks) that was at least twice the duration of their last prior treatment before entry into the study.

(Logo:  http://photos.prnewswire.com/prnh/20120628/LA32362LOGO)

In addition, the presentation highlighted that one of these 5 patients, a heavily pre-treated patient with small cell lung cancer, achieved a confirmed partial response. The patient received his first treatment of ME-344 in August 2012 and has now been on study for more than 61 weeks. His June 2013 scans showed a decrease of 32% in target lesions, which was confirmed in his most recent scans (August 2013). This patient and three others remain on study and continue weekly dosing.

"The observed radiographic partial response is promising, particularly in such a difficult-to-treat disease as small cell lung cancer," said presenter and co-investigator Jeffrey R. Infante, MD, Director, Drug Development at Sarah Cannon Research Institute and Tennessee Oncology. "In addition to tumor shrinkage, this patient has also demonstrated symptomatic improvement while on study, including decreased cough, shortness of breath and improved performance status. The results
'/>"/>

SOURCE MEI Pharma, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. AstraZeneca Neuroscience partners with ePharmaSolutions to optimize Clinical Trial Management
2. PharmaSphere: Early-Stage Technology Transfer Collaborations - Enabling Platform Technologies & Deal Synergies between Academia and the Pharmaceutical Industry
3. ePharmaSolutions Wins Major Award for Life Sciences Industry Innovation
4. In Q1 Public Biopharmas Shift Fundraising into Overdrive
5. Cumberland Pharmaceuticals And PT. SOHO Industri Pharmasi enter Into Exclusive Licensing Agreement For Caldolor In Indonesia
6. ePharmaSolutions Launches an Innovative Patient Recruitment Application for Windows 8
7. Edison Pharmaceuticals, Inc. signs licensing agreement with Dainippon Sumitomo Pharma Co., Ltd. for development & commercialization of orphan mitochondrial and adult central nervous system disease drugs
8. MEI Pharmas Mitochondrial Inhibitor Drug Candidate ME-344 Named One of Top 10 Oncology Products for 2012
9. Among Newly Diagnosed Type 2 Diabetes Patients, DPP-IV Inhibitors are the Leading Oral Therapies After Standard Metformin and Sulfonylurea
10. MEI Pharma Acquires PWT143, A Highly Selective PI3-Kinase Delta Inhibitor
11. Neurocrine Announces Phase IIb Results Of VMAT2 Inhibitor NBI-98854 For Treatment Of Tardive Dyskinesia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... Research and Markets has announced the addition of the ... Disorder) Market - Forecast to 2023" report to their ... human microbiome market is segmented by application, disease, product, and ... be valued as $294 million in 2019 and is poised ... period of 2019-2023. The market is driven by growing incidences ...
(Date:9/19/2014)... UBM Medica US announces that  ... help oncologists and other clinicians gain a better understanding ... targeted therapies and immunotherapies, discusses some of the latest ... Every September, Blood Cancer Awareness Month ... blood cancers—helping to increase survival rates and improve the ...
(Date:9/19/2014)... WALTHAM, Mass. , Sept. 19, 2014  Alere ... in rapid diagnostics, issued the following statement today in ... Combating Antibiotic-Resistant Bacteria. "As the global leader ... President for establishing a national strategy to address the ... continuing to work with the Administration on initiatives to ...
Breaking Medicine Technology:Global Human Microbiome (Diabetes, Obesity, Autoimmune, Cancer, Diarrhea, Mental Disorder) Market - Forecast to 2023 2Global Human Microbiome (Diabetes, Obesity, Autoimmune, Cancer, Diarrhea, Mental Disorder) Market - Forecast to 2023 3OncoTherapy Network Highlights National Blood Cancer Awareness Month 2OncoTherapy Network Highlights National Blood Cancer Awareness Month 3OncoTherapy Network Highlights National Blood Cancer Awareness Month 4Alere Applauds President's Executive Order Combating Antibiotic-Resistant Bacteria 2
(Date:9/19/2014)... kids transition from elementary to middle school, they are ... study. But the researchers studying U.S schoolkids ... physical bullying declines as students get older. Because ... address all types of bullying as well as differences ... The study was published recently in School Psychology ...
(Date:9/19/2014)... 19, 2014 Hastings and Hastings, a discount ... the industry, announces a record number of visitors to its ... variety of serious injury cases as well as auto accident ... bite related accident cases and others. Having served the state ... stood the test of time when it comes to dedicated ...
(Date:9/19/2014)... Rockville Centre, NY (PRWEB) September 19, 2014 ... 17, the manufacturers of the embattled blood-thinner Xarelto, named ... County Court of Common Pleas, have moved the court ... the cases do not have sufficient connection with Philadelphia.* ... & Development, et al. (No. 140304328; Pa. Comm. Pls., ...
(Date:9/19/2014)... -- Your brain structure could help predict how willing you ... Researchers at Yale University found those with greater volume in ... may be more likely to engage in risky behavior than ... study, funded by the U.S. National Institute on Aging, involved ... the Northeast. The researchers sought to determine how brain structure ...
(Date:9/19/2014)... 2014 (HealthDay News) -- The U.S. Food and Drug Administration ... Trulicity is part of a class of once-a-week injectable drugs ... 2 diabetes. "Trulicity is a new treatment option, ... regimens to control blood sugar levels in the overall management ... the FDA,s Office of Drug Evaluation II, said in an ...
Breaking Medicine News(10 mins):Health News: Cyberbullying Seems to Ramp Up in Middle School 2Health News:Hastings And Hastings Announces a Record Number of Visitors to Its New Phoenix Personal Injury Website 2Health News:Xarelto Makers Seek Dismissal of Cases Brought in Philadelphia, Notes Rottenstein Law Group LLP 2Health News:Xarelto Makers Seek Dismissal of Cases Brought in Philadelphia, Notes Rottenstein Law Group LLP 3Health News:Brain Structure Might Help Predict Risky Behavior 2Health News:FDA Approves Another Weekly Injectable Drug for Type 2 Diabetes 2
... child filed a motion in federal court today to confirm settlement ... The family alleged in the suit that the insurer wrongfully ... (ASD), on the baseless ground that the care was "experimental." ... at a court-ordered conference on Wednesday, June 17, 2009, Blue Cross ...
... between gray matter and dopamine levels in patients , ... levels of the neurotransmitter dopamine may explain brain gray ... study suggests. , Previous research found an association between ... wasn,t known, the researchers wrote. , In this new ...
... treatment delays and jeopardize care, review suggests, , FRIDAY, June ... lecturer at the University of Toronto, was enjoying a rare ... beeped. , "I answered the page, and there was the ... been calling repeatedly to try to get in touch with ...
... , Brio Active opens its doors this month, offering a ... its core. , , DENVER, June 19 Brio ... vibration, a relatively new fitness concept in the U.S., with ... strength, flexibility, balance, energy, bone density, and neuromuscular coordination. ...
... 19 Bertalan Mesko, medical blogger and health 2.0 consultant, ... by Federico Semeraro, MD and the D-Sign Team, that provides ... but not everyone is trained to be able to perform ... to do it through clear instructions and images. , ...
... WHITE PLAINS, N.Y., June 19 Kenneth A. May, former CEO ... Trustees of the March of Dimes, it was announced today. , ... for our mission, especially our Prematurity Campaign," said Dr. Jennifer L. ... Ken,s continued leadership as we work towards our goal of giving ...
Cached Medicine News:Health News:Blue Cross Blue Shield of Michigan Forced to Pay for Autism Care In Landmark Case 2Health News:Blue Cross Blue Shield of Michigan Forced to Pay for Autism Care In Landmark Case 3Health News:Pages to Doctors Don't Always Hit the Mark 2Health News:Pages to Doctors Don't Always Hit the Mark 3Health News:Brio Active Brings Whole Body Vibration Fitness to Cherry Hills Village 2
Each handle is designed to fit a specific trephine size....
Each handle is designed to fit a specific trephine size....
Reusable, stainless steel trephine with handle....
Reusable, stainless steel trephine with handle....
Medicine Products: